Kantarjian et al53 assessed the efficacy and protection of dasatinib, as in contrast with imatinib, for the initial-line therapy of CML-CP. 5 hundred and nineteen people with recently diagnosed CML-CP ended up randomly assigned to obtain dasatinib at a dose of a hundred mg as soon as everyday (259 sufferers) https://marionz111vof2.frewwebs.com/profile